source
- ai3Bio raises $48 million to develop T-cell targeting therapy for autoimmune diseaseai3Bio announced its emergence from stealth mode after securing $48 million in Series A funding. The round was led by UPMC Enterprises and Ziff Capital Partners and combines technology from Corner…
- AbbVie’s once-daily Parkinson’s pill receives FDA approvalAbbVie announced that the U.S. Food and Drug Administration has granted approval for its once‑daily oral therapy for Parkinson’s disease. The decision allows the product to be marketed in the Unite…